[go: up one dir, main page]

CL2018003319A1 - Compuestos de mic-1 y usos de estos. - Google Patents

Compuestos de mic-1 y usos de estos.

Info

Publication number
CL2018003319A1
CL2018003319A1 CL2018003319A CL2018003319A CL2018003319A1 CL 2018003319 A1 CL2018003319 A1 CL 2018003319A1 CL 2018003319 A CL2018003319 A CL 2018003319A CL 2018003319 A CL2018003319 A CL 2018003319A CL 2018003319 A1 CL2018003319 A1 CL 2018003319A1
Authority
CL
Chile
Prior art keywords
compounds
mic
amino acid
refers
extension
Prior art date
Application number
CL2018003319A
Other languages
English (en)
Inventor
Henning Thøgersen
Xujia Zhang
Xiang Gao
Hongtao Guan
Kristian Sass-Ørum
Lars Fogh Iversen
Per Nørgaard
Sebastian Beck Jørgensen
Kristian Tage Hansen
Yi Wang
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2018003319A1 publication Critical patent/CL2018003319A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE MIC-1. MÁS ESPECÍFICAMENTE, SE REFIERE A COMPUESTOS QUE COMPRENDEN UN POLIPÉPTIDO MIC-1 Y UNA EXTENSIÓN DE AMINOÁCIDO EN EL N-TERMINAL, EN DONDE DICHA EXTENSIÓN CONSISTE EN 3 A 36 RESIDUOS DE AMINOÁCIDOS Y DONDE EL COMPUESTO TIENE UN PI CALCULADO INFERIOR A 6.5. LOS COMPUESTOS DE LA INVENCIÓN TIENEN ACTIVIDAD DE MIC-1. LA INVENCIÓN SE REFIERE, ADEMÁS, A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS Y EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES, ASÍ COMO TAMBIÉN AL USO MÉDICO DE LOS COMPUESTOS.
CL2018003319A 2016-05-24 2018-11-21 Compuestos de mic-1 y usos de estos. CL2018003319A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016083104 2016-05-24
CN2016103574 2016-10-27

Publications (1)

Publication Number Publication Date
CL2018003319A1 true CL2018003319A1 (es) 2019-02-01

Family

ID=59009675

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003319A CL2018003319A1 (es) 2016-05-24 2018-11-21 Compuestos de mic-1 y usos de estos.

Country Status (18)

Country Link
US (3) US20190248852A1 (es)
EP (1) EP3463412A1 (es)
JP (1) JP7013390B2 (es)
KR (1) KR102433503B1 (es)
CN (1) CN109414471A (es)
AU (1) AU2017269496B2 (es)
BR (1) BR112018072034A2 (es)
CA (1) CA3025251A1 (es)
CL (1) CL2018003319A1 (es)
CO (1) CO2018012258A2 (es)
IL (1) IL262926A (es)
MA (1) MA45113A (es)
MX (1) MX2018014023A (es)
PE (1) PE20190117A1 (es)
PH (1) PH12018502465A1 (es)
SA (1) SA518400460B1 (es)
TW (1) TW201741333A (es)
WO (1) WO2017202936A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675353B2 (en) 2016-05-24 2020-06-09 Amgen Inc. Pegylated carfilzomib compounds

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3027642B1 (en) 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
EP3463412A1 (en) 2016-05-24 2019-04-10 Novo Nordisk A/S Mic-1 compounds and use thereof
EP3551214B1 (en) 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
SG11202009884YA (en) 2018-04-09 2020-11-27 Amgen Inc Growth differentiation factor 15 fusion proteins
EP3833974A2 (en) 2018-08-10 2021-06-16 Novartis AG Gfral extracellular domains and methods of use
EP4520343A3 (en) 2018-10-22 2025-05-21 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4237438A4 (en) 2020-10-27 2024-11-27 Beijing QL Biopharmaceutical Co., Ltd. GDF15 FUSION PROTEINS AND THEIR USE

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
CN1152942C (zh) 2000-05-30 2004-06-09 华东理工大学 含载流子传输功能团的分子扭曲型电致发光材料及其应用
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CA2905125C (en) 2004-04-13 2017-02-07 Samuel Norbert Breit Use of mic-1 or modulating agent thereof to modulate appetite or body weight
ATE444306T1 (de) 2004-05-13 2009-10-15 Lilly Co Eli Fgf-21-fusionsproteine
WO2006010891A2 (en) 2004-07-26 2006-02-02 Asterion Limited Linkers
JP2010505437A (ja) 2006-10-13 2010-02-25 ノボ ノルディスク ヘルス ケア アーゲー 塩基性タンパク質タグに融合したプロセシング酵素
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP2440228B8 (en) * 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9828415B2 (en) 2013-01-30 2017-11-28 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP3027642B1 (en) 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
BR112016029848A2 (pt) 2014-06-24 2017-10-24 Novo Nordisk As proteínas de fusão mic-1 e utilizações das mesmas
MX370115B (es) 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
CA2964808C (en) * 2014-10-30 2023-06-27 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
TWI681966B (zh) 2014-12-23 2020-01-11 丹麥商諾佛 儂迪克股份有限公司 Ｆｇｆ２１衍生物及其用途
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
TW201716432A (zh) 2015-07-06 2017-05-16 諾佛 儂迪克股份有限公司 新穎肽與肽衍生物及其用途
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
MD3355919T2 (ro) 2015-10-02 2023-02-28 Univ Wuerzburg J Maximilians Terapie combinată cu utilizarea inhibitorilor factorului de creștere și diferențiere uman 15 (GDF-15) și a blocanților punctelor de control imunitar
WO2017055612A1 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EP3463412A1 (en) 2016-05-24 2019-04-10 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675353B2 (en) 2016-05-24 2020-06-09 Amgen Inc. Pegylated carfilzomib compounds

Also Published As

Publication number Publication date
US20230212245A1 (en) 2023-07-06
JP2019520333A (ja) 2019-07-18
RU2018141829A (ru) 2020-06-25
MX2018014023A (es) 2019-04-04
KR102433503B1 (ko) 2022-08-18
PE20190117A1 (es) 2019-01-16
CN109414471A (zh) 2019-03-01
RU2018141829A3 (es) 2020-10-07
AU2017269496A1 (en) 2018-11-15
TW201741333A (zh) 2017-12-01
CO2018012258A2 (es) 2018-11-30
BR112018072034A2 (pt) 2019-02-12
IL262926A (en) 2018-12-31
PH12018502465A1 (en) 2019-04-08
US12006344B2 (en) 2024-06-11
AU2017269496B2 (en) 2021-03-25
EP3463412A1 (en) 2019-04-10
JP7013390B2 (ja) 2022-01-31
US20210198331A1 (en) 2021-07-01
WO2017202936A1 (en) 2017-11-30
SA518400460B1 (ar) 2022-09-21
CA3025251A1 (en) 2017-11-30
MA45113A (fr) 2019-04-10
KR20190008290A (ko) 2019-01-23
US20190248852A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
TW201613958A (en) MIC-1 fusion proteins and uses thereof
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
CL2016002389A1 (es) Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil
CL2017003201A1 (es) Variantes de il-37
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
BR112015007592A2 (pt) composições de enalapril
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
EA201791648A1 (ru) Комбинация гиалуроновой кислоты и макроголя и фармацевтические композиции, содержащие ее
AR111823A1 (es) Compuestos de mic-1 y sus usos